High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis

被引:1
作者
Bejko, Dritan [1 ,6 ]
Ernst, Corinna [1 ]
Vergison, Anne [1 ]
Stranges, Saverio [2 ,3 ,4 ,5 ]
Zeegers, Maurice P. [6 ]
Mossong, Joel [1 ]
机构
[1] Hlth Directorate, Hlth Inspectorate, Luxembourg, Luxembourg
[2] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[3] Western Univ, Dept Family Med, London, ON, Canada
[4] Western Univ, Dept Med, London, ON, Canada
[5] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[6] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Epidemiol, Maastricht, Netherlands
关键词
Vaccine effectiveness; Natural immunity; COVID-19; Retrospective cohort; Hospital admission; Mortality;
D O I
10.1016/j.vaccine.2024.05.059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to severe outcomes (i.e., hospitalisation, deaths) and estimated vaccine effectiveness (VE) as well as the role of immunity conferred by prior infections against severe outcomes in adults. Methods: We linked reported SARS-CoV-2 cases among residents aged >= 20 years with vaccination data and SARS-CoV-2 related hospitalisations and deaths. Cases were followed-up until day 14 for COVID-19 related hospital admission and up to day 28 for mortality after a positive test. We analysed the association between the vaccination status and severe forms using proportional Cox regression, adjusting for previous infection, age, sex and nursing homes residency. VE was measured as 1-adjusted hazard ratio of vaccinated vs unvaccinated individuals. The population preventable fraction was computed using the adjusted hazard ratio and the proportion of cases within the vaccination category. Results: Between December 2021, and March 2023, we recorded 187143 SARS-CoV-2 cases, 1 728 (0.93%) hospitalizations and 611 (0.33%) deaths. The risk of severe outcomes increased with age, was higher among men and nursing home residents. Compared to unvaccinated adults, VE against hospitalization was 38.8% (95%CI: 28.1%-47.8%) for a complete primary cycle of vaccination, 62.1% (95%CI: 57.0%-66.7%) for one booster, and 71.6% (95%CI: 66.7%-76.2%) for two booster doses. VE against death was respectively 49.5% (95%CI: 30.8%63.3%), 69.0% (95%CI: 61.2%-75.3%) and 76.2% (95%CI: 68.4%-82.2%). Previous infection was not associated with lower risk of hospitalisation or mortality. The vaccination lowered mortality by 55.8 % (95%CI: 46.3%62.8%) and reduced hospital admissions by 49.1% (95%CI: 43.4%-54.4%). Conclusions: Complete vaccination and booster but not previous infection were protective against hospitalization and death. The vaccination program in Luxembourg led to substantial reductions in SARS-CoV-2-related mortality and hospitalizations at the population level.
引用
收藏
页数:9
相关论文
共 27 条
  • [21] Palmer K, 2021, Eur Obs Health Syst Policies Cross Ctry Anal, V1, P2021
  • [22] Palmer K, 2022, Front Public Health, V18
  • [23] Peralta-Santos A, 2020, Briefing requested by the ENVI committee
  • [24] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Polack, Fernando P.
    Thomas, Stephen J.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Perez, John L.
    Perez Marc, Gonzalo
    Moreira, Edson D.
    Zerbini, Cristiano
    Bailey, Ruth
    Swanson, Kena A.
    Roychoudhury, Satrajit
    Koury, Kenneth
    Li, Ping
    Kalina, Warren V.
    Cooper, David
    Frenck, Robert W., Jr.
    Hammitt, Laura L.
    Tureci, Ozlem
    Nell, Haylene
    Schaefer, Axel
    Unal, Serhat
    Tresnan, Dina B.
    Mather, Susan
    Dormitzer, Philip R.
    Sahin, Ugur
    Jansen, Kathrin U.
    Gruber, William C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) : 2603 - 2615
  • [25] Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
    Sadoff, Jerald
    Gray, Glenda
    Vandebosch, An
    Cardenas, Vicky
    Shukarev, Georgi
    Grinsztejn, Beatriz
    Goepfert, Paul A.
    Truyers, Carla
    Fennema, Hein
    Spiessens, Bart
    Offergeld, Kim
    Scheper, Gert
    Taylor, Kimberly L.
    Robb, Merlin L.
    Treanor, John
    Barouch, Dan H.
    Stoddard, Jeffrey
    Ryser, Martin F.
    Marovich, Mary A.
    Neuzil, Kathleen M.
    Corey, Lawrence
    Cauwenberghs, Nancy
    Tanner, Tamzin
    Hardt, Karin
    Ruiz-Guinazu, Javier
    Le Gars, Mathieu
    Schuitemaker, Hanneke
    Van Hoof, Johan
    Struyf, Frank
    Douoguih, Macaya
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (23) : 2187 - 2201
  • [26] Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
    Song, Shangchen
    Madewell, Zachary J.
    Liu, Mingjin
    Longini, Ira M.
    Yang, Yang
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [27] Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity Comment
    Yahav, Dafna
    Yelin, Dana
    Eckerle, Isabella
    Eberhardt, Christiane S.
    Wang, Jianwei
    Cao, Bin
    Kaiser, Laurent
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (03) : 315 - 318